Types of RNA therapeutics

Goleij, Pouya; Babamohamadi, Mehregan; Rezaee, Aryan; Sanaye, Pantea Majma; Tabari, Mohammad Amin Khazeei; Sadreddini, Sarvin; Arefnezhad, Reza; Motedayyen, Hossein

doi:10.1016/bs.pmbts.2023.12.022

Cited by 2 publications

(1 citation statement)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRNAs) are a class of small, non-coding, singlestranded RNAs that regulate gene expression at the posttranscriptional level, impacting crucial cellular processes like proliferation, differentiation, and apoptosis (1)(2)(3)(4). This regulatory influence extends to an estimated 60% of human genes, highlighting their widespread impact (5).…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs and angiosarcoma: are there promising reports?

Modarresi Chahardehi,

Afrooghe,

Emtiazi

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

In recent years, microRNAs (miRNAs) have garnered increasing attention for their potential implications in cancer pathogenesis, functioning either as oncogenes or tumor suppressors. Notably, angiosarcoma, along with various other cardiovascular tumors such as lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations in the expression of specific miRNA subtypes. A substantial body of evidence underscores the pivotal involvement of miRNAs in the genesis of angiosarcoma and certain cardiovascular tumors. This review aims to delve into the current literature on miRNAs and their prospective applications in cardiovascular malignancies, with a specific focus on angiosarcoma. It comprehensively covers diagnostic methods, prognostic evaluations, and potential treatments while providing a recapitulation of angiosarcoma’s risk factors and molecular pathogenesis, with an emphasis on the role of miRNAs. These insights can serve as the groundwork for designing randomized control trials, ultimately facilitating the translation of these findings into clinical applications. Moving forward, it is imperative for studies to thoroughly scrutinize the advantages and disadvantages of miRNAs compared to current diagnostic and prognostic approaches in angiosarcoma and other cardiovascular tumors. Closing these knowledge gaps will be crucial for harnessing the full potential of miRNAs in the realm of angiosarcoma and cardiovascular tumor research.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNAs and angiosarcoma: are there promising reports?

Modarresi Chahardehi,

Afrooghe,

Emtiazi

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

Targeting the RUNX3–miR-186-3p–DAT–IGF1R axis as a therapeutic strategy in a Parkinson’s disease model

Huang,

Wan,

2024

J Transl Med

View full text Add to dashboard Cite

With the increasing age of the population worldwide, the incidence rate of Parkinson’s disease (PD) is increasing annually. Currently, the treatment strategy for PD only improves clinical symptoms. No effective treatment strategy can slow down the progression of the disease. In the present study, whole transcriptome sequencing was used to obtain the mRNA and miRNA expression profiles in a PD mouse model, which revealed the pathogenesis of PD. The transcription factor RUNX3 upregulated the miR-186-3p expression in the PD model. Furthermore, the high miR-186-3p expression in PD can be targeted to inhibit the DAT expression, resulting in a decrease in the dopamine content of dopaminergic neurons. Moreover, miR-186-3p can be targeted to inhibit the IGF1R expression and prevent the activation of the IGF1R – P-PI3K – P-AKT pathway, thus increasing the apoptosis of dopaminergic neurons by regulating the cytochrome c – Bax – cleaved caspase-3 pathway. Our research showed that the RUNX3 – miR-186-3p – DAT – IGF1R axis plays a key role in the pathogenesis of PD, and miR-186-3p is a potential target for the treatment of PD. Supplementary Information The online version contains supplementary material available at 10.1186/s12967-024-05535-7.

show abstract

Types of RNA therapeutics

Cited by 2 publications

References 108 publications

MicroRNAs and angiosarcoma: are there promising reports?

MicroRNAs and angiosarcoma: are there promising reports?

Targeting the RUNX3–miR-186-3p–DAT–IGF1R axis as a therapeutic strategy in a Parkinson’s disease model

Contact Info

Product

Resources

About